

Amendments to the Claims:

Please cancel claims 3 to 5 and 10 and add new claims 12 to 16 as forth
hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Currently Amended) A method for the preparation of *trans*- or *cis*-diammoniumdichlorodihydroxoplatinum(IV) or derivatives thereof,

characterized in that wherein

trans- or *cis*-diammoniumdichloroplatinum(II) is reacted with a solution comprising >30% peroxide at temperatures below 30°C, and

the product thus obtained is dissolved in a mineral acid and subsequently precipitated with an alkaline solution.

2. (Currently Amended) A compound of general formula



wherein X₁, X₂ = calcium, magnesium, sodium, potassium, lithium ions, alkyl and/or aryl residues.

3. to 5. (canceled)

6. (Original) A pharmaceutical agent, comprising a compound according to claim 2, optionally together with a pharmaceutically tolerable carrier, adjuvant and/or vehicle.

7. (Currently Amended) The pharmaceutical agent according to the preceding claim, characterized in that

claim 6, wherein the carriers are selected from the group comprising fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.

8. (Currently Amended) The pharmaceutical agent according to any of the preceding claims,

characterized in that

claim 6, wherein

the carriers are liposomes, siosomes and/or niosomes.

9. (Original) A kit comprising the compounds according to claim 2, optionally together with information for combining the contents of the kit.

10. (canceled)

11.(New) A method for prophylaxis, therapy, follow-up and aftercare of a disease associated with cell growth, cell differentiation and/or cell division comprising

administering the compound of claim 2 to a person in need of such prophylaxis, therapy, follow-up or aftercare for a disease associated with cell growth, cell differentiation and/or cell division in a prophylactically, therapeutically, follow-up or aftercare effective amount.

12.(New) The method of claim 11, wherein said disease is a tumor.

13.(New) The method of claim 11, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

14.(New) The method of claim 12, wherein the compound is administered orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly,

intraperitoneally, regionally and/or topically.

15. (New) A combination tumor therapy comprising
administering the compound of claim 2 to a person in need of such therapy in
a therapeutically effective amount, and
subjecting said person to a second tumor treatment.
16. (New) The combination therapy of claim 15, wherein said second tumor treatment is
chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.